glp 1 increase sex drive Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it Are Sexual Side Effects Emerging

The neuroprotective effects of glucagon-like peptide 1 in Alzheimers and Parkinsons disease: an in-depth review

Requirement/ Importance : It can be synthesised in the body, but deficiency has been reported which can be a result of impaired CoQ10 synthesis due to nutritional deficiencies, a genetic defect in CoQ10 synthesis, ageing or increased tissue needs

The potential use of plant natural products and plant extracts with antioxidant properties for the prevention/treatment of neurodegenerative diseases: in vitro, in vivo and clinical trials

Specific Causation A successful GLP-1 claim requires proof of both: General causation : Whether the drug is capable of causing the alleged injury Specific causation : Whether the drug actually caused the injury in the individual plaintiff Scientific literature, pharmacovigilance data, and regulatory findings are critical in establishing general causation